Expression of telomerase reverse transcriptase in peripheral T-cell lymphoma

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Telomere length maintenance by telomerase is crucial for cancer cell proliferation.
• The catalytic reverse transcriptase protein (TERT) is key to telomerase activation.
• Peripheral T-cell lymphomas (PTCL) are aggressive non-Hodgkin lymphomas with diverse subtypes.

Purpose of the Study:

• To investigate the role and prognostic significance of TERT in PTCL subtypes.
• To analyze TERT expression, promoter mutations, and copy number variations in PTCL.
• To explore potential non-telomeric roles of TERT in PTCL pathogenesis.

Main Methods:

• Immunohistochemistry was used to assess TERT protein expression in PTCL tissues.
• TERT promoter mutation analysis and genomic copy number evaluation were performed.
• Statistical analysis correlated TERT expression with clinicopathological features and patient prognosis.

Main Results:

• TERT expression was detected in 31% of AITL, 11% of PTCL-NOS, and 5% of ATLL, with AITL showing significantly high expression.
• TERT promoter mutations were found in 2/40 PTCL-NOS cases.
• Genome copy number amplification occurred in 33% of PTCL-NOS, 33% of AITL, and 50% of ATLL.
• No clear correlation was observed between TERT genomic abnormalities and protein expression.
• Cytoplasmic TERT expression was noted, suggesting non-telomeric functions.
• TERT expression trended towards a poor prognosis in PTCL-NOS, but was not an independent factor.

Conclusions:

• TERT is frequently expressed in AITL and may be implicated in PTCL pathogenesis.
• TERT expression in PTCL-NOS is associated with a poorer prognosis, warranting further investigation.
• The cytoplasmic localization of TERT suggests roles beyond telomere maintenance in PTCL.